B

Biotoxtech Co Ltd
KOSDAQ:086040

Watchlist Manager
Biotoxtech Co Ltd
KOSDAQ:086040
Watchlist
Price: 2 860 KRW 1.6%
Market Cap: 45.6B KRW

Biotoxtech Co Ltd
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Biotoxtech Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
B
Biotoxtech Co Ltd
KOSDAQ:086040
Cash from Operating Activities
-â‚©3.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-3%
Samsung Biologics Co Ltd
KRX:207940
Cash from Operating Activities
â‚©2.2T
CAGR 3-Years
43%
CAGR 5-Years
38%
CAGR 10-Years
N/A
S
ST Pharm Co Ltd
KOSDAQ:237690
Cash from Operating Activities
â‚©70.6B
CAGR 3-Years
121%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Cash from Operating Activities
-â‚©970.2m
CAGR 3-Years
29%
CAGR 5-Years
25%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Cash from Operating Activities
-â‚©47.1B
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
-17%
N
NanoEnTek Inc
KOSDAQ:039860
Cash from Operating Activities
-â‚©1.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
7%
No Stocks Found

Biotoxtech Co Ltd
Glance View

Biotoxtech Co., Ltd. engages in the provision of non-clinical drug trials. The company is headquartered in Cheongju, Chungcheongbuk-Do. The company went IPO on 2007-09-21. The firm provides safety evaluation research, efficacy evaluation research and analysis research. Its safety evaluation research business provides general toxicity tests, local toxicity tests, reproductive and development tests, genotoxicity tests, immunotoxicity tests, carcinogenicity tests, safety pharmacology tests, ecotoxicology tests, histopathology tests and hematology tests. Its efficacy evaluation research business provides efficacy evaluation of medical supplies, health supplements and cosmetics. Its analysis research business provides pharmacokinetics (PK) tests and toxicokinetics (TK) tests services, as well as validation and bio analysis services. On March 13, 2013, the Company acquired a 60% stake in its new established subsidiary.

Intrinsic Value
3 931.75 KRW
Undervaluation 27%
Intrinsic Value
Price
B

See Also

What is Biotoxtech Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
-3.6B KRW

Based on the financial report for Jun 30, 2025, Biotoxtech Co Ltd's Cash from Operating Activities amounts to -3.6B KRW.

What is Biotoxtech Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-3%

Over the last year, the Cash from Operating Activities growth was 58%.

Back to Top